home / stock / glpg / glpg articles
Mechelen, Belgium; 6 December 2023, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that it will host a Key Opinion Lead...
First nine months 2023 key financials: Group revenues of €448.9 million Jyseleca® net sales of €82.1 million Cash and current financi...
Transaction would enable Galapagos to realize considerable annualized savings and accelerate its pipeline focused on developing transformational ...
GLPG3667 is an investigational, novel, oral, reversible, and selective tyrosine kinase 2 (TYK2) inhibitor GLPG3667 is currently in developmen...
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...
2024-05-11 10:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...